First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children’s Oncology Group Phase 1/Pilot Consortium

PURPOSE: Characterize the pharmacokinetics of oral crizotinib in children with cancer. METHODS: Sixty-four children with solid tumors or anaplastic large-cell lymphoma (ALCL) enrolled on a phase 1/2 trial of the ALK, MET and ROS1 inhibitor, crizotinib, had pharmacokinetic sampling after the first do...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Chemother Pharmacol
Autors principals: Balis, Frank M., Thompson, Patrick A., Mosse, Yael P., Blaney, Susan M., Minard, Charles G., Weigel, Brenda J., Fox, Elizabeth
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2016
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5225209/
https://ncbi.nlm.nih.gov/pubmed/28032129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3220-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars